Compare IOSP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOSP | AUPH |
|---|---|---|
| Founded | 1938 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 1998 | 2014 |
| Metric | IOSP | AUPH |
|---|---|---|
| Price | $68.65 | $13.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $124.00 | $17.25 |
| AVG Volume (30 Days) | 200.5K | ★ 903.8K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | 228.87 | ★ 5075.00 |
| EPS | ★ 4.67 | 2.07 |
| Revenue | ★ $1,778,000,000.00 | $283,055,000.00 |
| Revenue This Year | $5.96 | $17.35 |
| Revenue Next Year | $6.10 | $15.66 |
| P/E Ratio | $14.74 | ★ $6.95 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $68.67 | $6.83 |
| 52 Week High | $99.63 | $16.54 |
| Indicator | IOSP | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 21.23 | 41.68 |
| Support Level | N/A | $13.52 |
| Resistance Level | $76.78 | $15.23 |
| Average True Range (ATR) | 2.04 | 0.57 |
| MACD | -1.04 | 0.00 |
| Stochastic Oscillator | 4.38 | 24.42 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Performance Chemicals segment that derives maximum revenue, provides technology-based solutions for its customers' processes or products in personal care, home care, agrochemical, construction, mining and other industrial markets. The Fuel Specialties segment develops, manufactures, blends, markets and supplies a range of specialty chemical products used as additives in diesel, jet, marine, fuel oil and other fuels. The Oilfield Services segment develops and markets chemical solutions for drilling, completion, production, DRA and oil and gas applications.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.